You are here

Multiple Indication Adjuvants

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911NF-08-C-0044
Agency Tracking Number: C081-105-0080
Amount: $99,985.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD08-105
Solicitation Number: 2008.1
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): 2008-05-05
Award End Date (Contract End Date): 2008-11-05
Small Business Information
2901 South Loop Drive Suite 3360
Ames, IA 50010
United States
DUNS: 606727076
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Ramon Flick
 Senior Director of Vaccine Developm
 (515) 296-3944
Business Contact
 Carl Langren
Title: Chief Financial Officer
Phone: (515) 309-0138
Research Institution

The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift Valley fever virus (RVFV, bunyavirus), and Lassa virus (LV, arenavirus), to evaluate the adjuvant potency of the alphaGal Adjuvant Technology. This technology is based on the innate naturally acquired human immune response to galactose alpha(1,3)galactose alpha(1,4)N-acetylglucosamine (alphaGal) epitopes. In Phase I we will illustrate the broad application of the alphaGal Adjuvant Technology to antiviral vaccines by demonstrating that alphaGal-modification significantly enhances and modulates the immune response to select vaccines in a mouse model. In the Phase I Option, the optimized adjuvant conditions eliciting the best immune response to the different tested antiviral vaccines, based upon the mouse model immunological data, will be utilized in limited lethal challenge efficacy experiments to be conducted with wild-type virus under Biosafety Level (BSL)-4 conditions in the mouse model. Significant efficacy will lead to a Phase II proposal and further studies involving adjuvant efficacy in small rodents and non-human primates.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government